Overview

* Abeona Q2 net income of $108.8 mln beats analyst expectations, per LSEG data

* Adjusted EPS of $1.71 beats estimates, driven sale of Rare Pediatric Disease priority review voucher (PRVsale)

* ZEVASKYN U.S. launch on track and first patient treatment expected in Q3

* Says with Abeona transitioning into a commercial organization, some manufacturing and development costs reclassified from R&D expense to inventory or SG&A expenses.

Outlook

* Abeona expects first ZEVASKYN treatment in Q3

* Company anticipates profitability in 1H 2026

* Company plans to scale ZEVASKYN supply to 10 patients/month by mid-2026

Result Drivers

* FDA APPROVAL - ZEVASKYN received FDA approval in April 2025 for treating RDEB, marking a key milestone for Abeona

* STRONG PATIENT INTEREST - High demand for ZEVASKYN with multiple patients identified and progressing towards treatment, per CEO Vish Seshadri

* INSURANCE COVERAGE - Positive insurance coverage established with major national and regional payers, facilitating broad patient access

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS Beat $1.71 -$0.39

(5

Analysts

)

Q2 Net Beat $108.83 -$19.40

Income mln mln (5

Analysts

)

Q2 Miss -$22.79 -$19.30

Income mln mln (6

From Analysts

Operatio )

ns

Q2 Cash $225.90

& mln

Investme

nts

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Abeona Therapeutics Inc ( ABEO ) is $20.00, about 67.2% above its August 13 closing price of $6.56

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)